Targeting Bruton’s Tyrosine Kinase in CLL

Inhye E. Ahn¹ and Jennifer R. Brown²*

¹ Lymphoid Malignancies Section, National Heart, Lung, and Blood Institute, Bethesda, MD, United States, ² Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States

Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas. Covalent BTK inhibitors (BTKis) led to an unprecedented improvement in outcome in CLL, in particular for high-risk subgroups with TP53 aberration and unmutated immunoglobulin heavy-chain variable-region gene (IGHV). Ibrutinib and acalabrutinib are approved by the US Food and Drug Administration for the treatment of CLL and other B-cell lymphomas, and zanubrutinib, for patients with mantle cell lymphoma. Distinct target selectivity of individual BTKis confer differences in target-mediated as well as off-target adverse effects. Disease progression on covalent BTKis, driven by histologic transformation or selective expansion of BTK and PLCG2 mutated CLL clones, remains a major challenge in the field. Fixed duration combination regimens and reversible BTKis with non-covalent binding chemistry hold promise for the prevention and treatment of BTKi-resistant disease.

Keywords: Bruton’s tyrosine kinase, chronic lymphocytic leukemia, B-cell receptor signaling pathway, ibrutinib, acalabrutinib, zanubrutinib

INTRODUCTION

B cell receptor (BCR) signaling is an essential component of normal B cell development and malignant B cell survival (Figure 1). There are two types of BCR signaling: chronically activated BCR and tonic BCR. Activated BCR signaling is an antigen-dependent process utilizing the canonical nuclear factor-κB (NF-κB) pathway (1). Antigen binding by surface immunoglobulin initiates BCR signaling, resulting in coupling and autophosphorylation of the CD79A/CD79B heterodimer by Src family kinases (2). The phosphorylation of the immunoreceptor tyrosine-based activation motif recruits a cascade of signaling molecules. These include spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK), phospholipase Cγ2 (PLCγ2), and protein kinase C, which lead to activation of NF-κB, phosphatidylinositol 3-kinase (PI3K) and ERK. Tonic BCR is an antigen-independent process that maintains B cell survival through PI3K-AKT-mTOR signaling rather than NF-κB (3, 4). PI3Kδ is a proximal component of the BCR signaling pathway involved in both tonic and chronic activated signaling.

The distinction between tonic and chronically activated BCR signaling is clinically relevant as it mirrors disease sensitivity to BTK inhibition. BTK inhibition alone is ineffective for the treatment of germinal center B diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma with tonic BCR signaling, which require additional therapeutic targets such as SYK and CXCR4 (5–7). In contrast, lymphoma subtypes with activated BCR signaling are sensitive to BTK inhibitors (BTKis), and...
include chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and activated B cell (ABC) DLBCL. CLL and MCL have a non-genetic mechanism of BCR signaling where stereotyped BCRs and biased usage of unmutated immunoglobulin heavy-chain variable-region gene (IGHV) support the presence of cognate self-antigen leading to chronic BCR activation (8, 9). MZL also has a non-genetic mechanism of chronic BCR activation and is often associated with hepatitis C virus or *Helicobacter pylori* infection which provides a chronic antigenic stimulus to the BCR (10). ABC-DLBCL is characterized by genomic alterations of the BCR pathway and its downstream components (i.e. CD79A/B, CARD11) (11–13). Such mutations or amplification of genes in the BCR pathway and its downstream components (i.e. CD79A/B, CARD11) (11–13). Such mutations or amplification of genes in the BCR signaling pathway have not been reported in CLL (1–14) or MZL (1), and are rare in other indolent lymphomas (15, 16). Follicular lymphoma (FL) appears to have heterogeneous mechanisms of BCR activation. Although FL utilizes nonstereotyped BCR (17), studies have demonstrated antigen-mediated BCR signaling in a subset, not all, of FL (18, 19).

Of several approaches available for targeting the BCR pathway, BTK inhibition is the most popular and advanced in drug development. The U.S. Food and Drug Administration (FDA) has approved three BTKis for the treatment of B cell malignancies and graft-versus-host disease (GVHD): ibrutinib, acalabrutinib, and zanubrutinib. PI3K inhibition is another important BCR targeting strategy with four FDA-approved agents for the treatment of B cell malignancies (idelalisib, duvelisib, copanlisib, umbralisib). Isoform selectivity and potency of individual PI3K inhibitors contribute to observed differences in immune-mediated adverse events. The rates and severity of inflammatory toxicity, typically presenting as enteritis, hepatotoxicity, or pneumonitis, are relatively high with idelalisib. The rationale behind this observation is that idelalisib selectively inactivates the PI3K p110δ isoform in regulatory T cells thereby activating immune response (20, 21). Immune-mediated toxicity can be improved by less potent PI3Kδ inhibition via umbralisib, by targeting additional PI3K isoforms via copanlisib (pan-PI3K inhibitor), or in the relapsed/refractory setting where the immune effector function is downregulated (22). MALT1 inhibition is in the early stages of clinical development with no FDA-approved agent to date (23). We focus our discussion here on the successes and challenges of BTK inhibition in CLL, a malignant B cell disease with the most abundant data available on this topic.

**COVALENT BTK INHIBITORS**

Ibrutinib is the first-in-class, orally bioavailable, covalent BTKi. Ibrutinib binds to the cysteine 481 (C481) residue of BTK and irreversibly blocks phosphorylation of downstream kinases in the BCR signaling pathway (24). Since its discovery in 2007 (25), ibrutinib underwent rapid drug development leading to its initial FDA approval for the treatment of MCL in November 2013,
followed by expansion of approved indications to include CLL in 2014 and other hematologic diseases thereafter (Table 1). The approved doses of ibrutinib are 420mg once daily for CLL, Waldenström’s macroglobulinemia (WM), and chronic GVHD, and 560mg for MCL and MZL. Both of these doses achieve sustained and complete BTK occupancy (>95%) (26). While ibrutinib is most potent against BTK (half maximal inhibitory concentration \([IC_{50}] 0.5nM\)), it can also inhibit other targets at lower potency such as EGFR \([IC_{50}] 5.6nM\), ErbB2 \([IC_{50}] 9.4nM\), ITK \([IC_{50}] 10.7nM\), and TEC \([IC_{50}] 78nM\) (24). Many of these unintended targets of ibrutinib have a conserved cysteine residue aligning with the C481 in BTK. Their inhibition is a proposed mechanism of ibrutinib toxicity. In particular, bleeding and cardiac arrhythmia are among the important side effects of ibrutinib, which are thought to be related to inhibition of TEC family kinases involved in platelet activation (27) and inhibition of C-terminal Src kinase expressed in cardiac tissue (28).

To reduce toxicity and improve the tolerability of BTKis, alternative agents with more selective kinase inhibition profiles have been investigated. Acalabrutinib is a covalent BTKi with less potent inhibition of TEC compared to ibrutinib \([IC_{50}] 93nM\) for acalabrutinib vs. 7nM for ibrutinib in a comparative recombinant kinase assay) and no EGFR or ITK inhibition \([IC_{50}>1,000nM\) for both targets) (29). Acalabrutinib is approved for the treatment of CLL and MCL in the United States. For both diseases, acalabrutinib is dosed at 100mg PO twice daily. Studies have shown that the twice-daily dosing of acalabrutinib achieves the least variability at steady-state trough (29) and higher BTK occupancy (30) compared to 200mg given once daily.

In 2019, the FDA granted accelerated approval of zanubrutinib for the treatment of MCL. Zanubrutinib has less potent ITK and EGFR inhibition and a more favorable pharmacokinetic profile than ibrutinib (31). The twice daily dosing of zanubrutinib achieves 8-fold higher plasma drug exposure than ibrutinib and a longer half-life than acalabrutinib (4 vs. 1 hour), which effectively blocks the function of newly synthesized BTK protein as well as pre-existing BTK irreversibly bound by zanubrutinib. A phase 1 study did show higher BTK occupancy with twice daily (>95%) than once daily dosing (89%) of zanubrutinib in lymphoid tissue (31). The same study, however, showed uniformly high BTK occupancy in blood and no difference in clinical outcome across once- and twice-daily dosing groups. Both doses of zanubrutinib are being marketed. Taken together, the positive correlation between pharmacokinetics and BTK inhibition in lymphoid tissue provides a theoretical basis for zanubrutinib being a better covalent BTKi than others. Longer follow-up coupled with correlative studies are needed to determine whether more effective blockade of BTK resynthesis translates to deeper and more durable response to zanubrutinib.

Spebrutinib and tirabrutinib are covalent BTKis without regulatory approval in the United States. Spebrutinib is less selective than other BTKis and was withdrawn from development due to lack of efficacy (32). Tirabrutinib is a
selective BTKi approved in Japan for the treatment of primary CNS lymphoma, WM, and lymphoplasmacytic lymphoma (33, 34).

Despite the limited amount of high-quality evidence, emerging data indicate that selective BTKis may be safer and potentially more efficacious than ibrutinib. In the phase 3 ASPEN study for WM, the zanubrutinib arm achieved numerically higher rates of complete or very good partial responses (28%) than the ibrutinib arm (19%) without reaching statistical significance for the difference (35). Zanubrutinib was associated with a lower frequency and severity of bleeding and cardiovascular toxicities. The observed rate of atrial fibrillation, for instance, was 0.1 per 100 person-months with zanubrutinib compared to 1 per 100 person-months with ibrutinib. Indirect, prospective evidence further supports improved tolerability of second-generation BTKis. An open-label study of 33 CLL patients with ibrutinib intolerance reported 72% of the patients had tolerated acalabrutinib without having recurrences of ibrutinib-related adverse events (36). Two randomized studies ongoing in relapsed/refractory (R/R) CLL are expected to provide a direct comparison of first- and second-generation BTKis (ibrutinib vs. acalabrutinib, NCT02477696; ibrutinib vs. zanubrutinib, NCT03734016). Further research is needed to determine the comparative safety and efficacy of different BTKis including investigations in treatment-naïve (TN) CLL, long-term follow-up, and pharmacodynamic assessments of BTK and other targets.

**CLINICAL ACTIVITY**

BTKis pioneered the major shift in therapeutic approaches for CLL from chemoimmunotherapy to targeted therapy (Table 2). In randomized studies, single-agent ibrutinib demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to conventional single-agent chemo- or immunotherapy in TN (55) and R/R CLL (42). In the TN setting, BTKi-containing regimens outperformed doublet or triplet chemoimmunotherapy regimens by improving PFS in four randomized studies (37–39, 49) and OS in one of the four studies (38).

Patients who were classically considered to have high-risk characteristics benefit the most from BTKis (56, 57). TP53 aberration, referring to a mutation of the TP53 tumor suppressor gene or deletion of chromosome 17p where TP53 is encoded, is a strong negative prognostic marker in CLL (58). First-line treatment with an intensive chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) reported median PFS of 15 months for patients with TP53 aberration as opposed to nearly 5 years for those without the aberration (48, 54). Treatment with BTKis substantially extended the survival of patients with TP53 aberration (48, 59) with the observed rates of 5-year PFS and OS being 70% and 85%, respectively, when ibrutinib was first-line therapy (47). Patients with unmutated IGHV, another high-risk genetic marker in CLL, also achieved superior PFS with BTKi-based therapy compared to chemoimmunotherapy (37–39, 49). However, such PFS benefit was not observed in the subgroup with mutated IGHV. Outcome data based on the IGHV mutation status should be interpreted with caution because of relatively short follow-up and small numbers of events at the time of analyses. Equally critical to consider is long-lasting remission—and possibly cure—observed after treatment with FCR in a subset of patients with mutated IGHV (60, 61). Chemoimmunotherapy remains an option for young and fit CLL patients with mutated IGHV who prefer a defined duration of treatment to avoid concerns of long-term toxicity, treatment adherence, and financial burden related to continuous BTKi therapy.

Although covalent BTKis provide an excellent disease control in most patients, BTK inhibition alone is insufficient to eradicate CLL or achieve deep responses. Undetectable minimal residual disease (U-MRD) with fewer than 1 CLL cell per 10,000 leukocytes is rarely observed with ibrutinib (46, 59) or acalabrutinib alone (<7%) (49). Depth of response marginally improves with prolonged therapy (33% reduction of circulating CLL cells with each additional year on ibrutinib) (59). To improve the efficacy of BTKis, multiple trials have tested the combination of BTKis with the following chemoimmunotherapy regimens: anti-CD20 monoclonal antibodies (mAbs) (37–39, 46, 49, 53, 62), fludarabine (63), bendamustine (64), FCR (65), fludarabine, cyclophosphamide plus obinutuzumab (66, 67), and bendamustine plus rituximab (BR) (44, 68). A few exceptional studies used conventional agents for an abbreviated period as part of sequential therapy (64, 66), debulking (63), or MRD clearance (67). The vast majority of the combination studies adopted up to six cycles of conventional therapy. Combination approaches did improve the rate of U-MRD up to 80-90% by adding triplet chemoimmunotherapy to ibrutinib (65–67), and a range of 5-35% by adding an anti-CD20 to a BTKi in TN CLL (37–39, 46, 49, 53, 62). Despite high rates of U-MRD, cytotoxic agents have fallen out of favor because of safety concerns related to hematologic toxicities and secondary myeloid neoplasms observed in 2-5% of long-term survivors treated with FCR (61, 69).

The combination of an anti-CD20 mAb and a BTKi is generally well tolerated, and its use is supported by U.S. prescriber information for ibrutinib and acalabrutinib. Nevertheless, it is unclear if mAbs add clinically meaningful benefit to BTK inhibition. Several thoughtfully designed randomized trials tackled this question and arrived at different conclusions. A randomized phase 2 study enrolling mostly R/R CLL patients showed no difference in PFS with or without the addition of rituximab to ibrutinib (46). A randomized phase 3 study in elderly TN CLL reached a similar conclusion (37). Nevertheless, trials testing newer generations of BTKis and anti-CD20 mAbs challenge previous observations. The GENUINE study showed significant PFS benefit with the addition of ublituximab to ibrutinib, and the PFS benefit was largely driven by high-risk patients with R/R disease and TP53 aberration (70). The ELEVATE-TN study also reported 50% reduction in risk of progression or death in patients treated with acalabrutinib plus obinutuzumab compared to those receiving...
| References | Phase | Patient population | Median FU | Primary endpoint | BTKi arm N, therapy | Control arm N, therapy | Comments |
|------------|-------|--------------------|-----------|------------------|----------------------|------------------------|----------|
| **Ibrutinib** | | | | | | | |
| Alliance 041702 (37) | 3 | TN CLL with age ≥65Y | 38M | PFS | 180, Ibru | 176, BR | 3 treatment arms, no PFS difference between two BTKi containing arms |
| ECOG-ACRIN 1912 (38) | 3 | TN CLL with age ≤70Y | 34M | PFS | 354, Ibru-R | 175, FCR | Excluded del17p, improved OS with BTKi (P<0.001) |
| iLLUMINATE (39) | 3 | TN CLL with age ≥65Y or comorbidities | 31M | PFS | 113, Ibru-G | 116, Chlb-G | Less infusion-related reactions with Ibru-G (25%) than Chlb-G (58%) |
| RESONATE-2 (40, 41) | 3 | TN CLL with age ≥65Y | 60M | PFS | 136, Ibru | 133, Chlb | Excluded del17p |
| RESONATE (42, 43) | 3 | RR CLL | 60M | PFS | 195, Ibru | 196, G | Excluded del17p |
| HELIOS (44, 45) | 3 | RR CLL | 35M | PFS | 289, Ibru-BR | 289, BR | Excluded del17p, OS benefit with Ibru-BR despite crossover |
| Burger et al. (46) | 2 | RR, or TN CLL with TP53 aberration | 36M | PFS | 104, Ibru | 104, Ibru-R | No PFS or OS difference between two Ibr arms |
| Ahn et al. (47) | 2 | TN CLL with TP53 aberration | 78M | Overall response | 34, Ibru | 85% at 5Y | TN subset of a phase 2 study |
| RESONATE-17 (48) | 2 | RR CLL with TP53 aberration | 28M | Overall response | 145, Ibru | 63% at 2Y | |
| **Acalabrutinib** | | | | | | | |
| ELEVATE-TN (49) | 3 | TN CLL | 28M | PFS | 179, Acala | 177, Chlb-G | 3 treatment arms, PFS difference between two Acala arms |
| ASCEND (50) | 3 | RR CLL | 16M | PFS | 155, Acala | 155, Idela-R | Most (77%) patients in the control arm received Idela-R rather than BR (23%). |
| Byrd et al. (51, 52) | 1/2 | RR CLL with TP53 aberration | 41M | Safety, efficacy | 27, Acala | 36M | Median |
| **Zanubrutinib** | | | | | | | |
| Tam et al. (53) | 1b | RR CLL | 29M | Safety | 45, Zanu | 91% at 2Y | CLL cohort of the phase 1 study |
| SEQUOIA Arm C (54) | 3** | TN CLL with TP53 aberration | 18M | Efficacy | 109, Zanu | – | |

*A Duration of response at 2 years, PFS was not reported.

**Non-randomized arm of the phase 3 study.
acalabrutinib alone (49). Across four randomized trials testing ibrutinib- or acalabrutinib-based combinations, there was a greater risk reduction in studies adding obinutuzumab to a BTKi (hazard ratio [HR] for progression or death 0.08-0.15) (39, 49) than those adding rituximab to a BTKi (HR 0.26-0.51) (37, 38) in patients with unmutated IGHV. Although these data are limited as they are often exploratory or subgroup analyses of trials, nonetheless they raise an important question of whether BTK inhibition can be optimized by using specific drug combinations in selected patient populations.

Why did randomized trials testing the combination of anti-CD20 mAbs and BTKis draw contradicting conclusions? This is because effector mechanisms of mAbs vary by molecules and by BTKis used in combination. The newer generation of anti-CD20 mAbs exhibits improved effector function compared to rituximab and has been shown to circumvent mechanisms of rituximab failure in vitro. Obinutuzumab, a glycoengineered type 2 antibody, induces greater direct cell killing, greater antibody-dependent cellular cytotoxicity (ADCC), and less intra- and trans-cellular loss of target antigens compared to rituximab (71). Ublituximab is a glycoengineered type 1 antibody that targets a unique epitope of CD20 and has shown greater ADCC than rituximab in vitro (72). In support of these findings, two randomized studies conducted in context of chemoimmunotherapy favored obinutuzumab to be more efficacious than rituximab for the treatment of TN CLL (73, 74) and FL (75). These effector mechanisms of mAbs can be hampered by off target effects of ibrutinib but preserved with the use of more selective BTKis. In a preclinical study, a wide range of doses of ibrutinib, but not acalabrutinib, inhibited antibody-dependent cellular phagocytosis, a key therapeutic mechanism of any anti-CD20 mAb (76). Ibrutinib also downregulates CD20 expression via decreased NF-xB activity (77) and by reducing supportive chemokines from the microenvironment that are necessary for CD20 upregulation (78). No data specific to the dynamics of CD20 expression during treatment with second-generation BTKis have yet been generated.

Venetoclax, a BCL2 inhibitor, is one of the preferred partners to BTKis. Single-agent venetoclax can achieve U-MRD in bone marrow in 16% of R/R CLL (79). The rate of U-MRD in bone marrow increases to ~60% in TN CLL by combining venetoclax with either obinutuzumab (80) or ibrutinib (81). Early data from single-arm trials testing triplet therapy with a BTKi, venetoclax, and obinutuzumab reported further improvement in the proportion of patients achieving deep responses. In TN CLL, the rate of U-MRD in bone marrow was 67% with ibrutinib, venetoclax and obinutuzumab (82), 78% with acalabrutinib, venetoclax and obinutuzumab (83), and 84% with zanubrutinib, venetoclax and obinutuzumab (84). Simultaneous targeting of BCL2 and BTK with or without an anti-CD20 mAb has several advantages over single-agent approaches. Targeted combinations can achieve U-MRD in a substantial proportion of patients, enabling treatment cessation after a fixed period (NCT04608318, NCT03701282, NCT02950051) or based on MRD status (NCT04639362). Such modifications in treatment duration, which are being actively investigated in clinical trials, can potentially reduce long-term toxicities linked to continuous therapy. Moreover, a lead-in period with a BTKi and/or obinutuzumab can reduce risk of tumor lysis syndrome (TLS), a potentially fatal toxicity of venetoclax (82). BTKis can additionally reduce the rate and the severity of infusion-related reactions (IRR) associated with mAbs. The reported rate of IRR was 44% in patients treated with venetoclax and obinutuzumab (80) and 20% in a different study testing acalabrutinib, venetoclax and obinutuzumab (85). Similar findings were reported from a randomized study for WM, which demonstrated a significantly lower rate of IRR in patients receiving ibrutinib and rituximab (1%) than in those treated with ibrutinib alone (16%) (86).

**SAFETY**

Safety profiles of individual BTKis have shared features and differences depending on relative selectivity to BTK. Because ibrutinib has the largest and longest safety data available among BTKis, our discussion focuses on key non-hematologic toxicities originally identified from ibrutinib and highlights differences in safety profiles of BTKis.

BTKis increase the risk of bleeding by inhibiting platelet aggregation and adhesion (87). BTK has been experimentally shown to be necessary for collagen-induced and von Willebrand factor-dependent thrombus formation (88). Further, both BTK and TEC are independently involved in platelet activation through glycoprotein (GP) VI signaling (89). Treatment with ibrutinib can block the downstream GP VI signaling and subsequent platelet aggregation, although there is substantial inter-patient variability in the effects of ibrutinib on platelet functions (90, 91). Compared with ibrutinib, acalabrutinib is less effective at inhibiting GP VI signaling in vitro and overall weaker at inhibiting collagen-mediated platelet aggregation ex vivo (92). Nevertheless, acalabrutinib still impacts platelet aggregation in certain settings such as in the presence of concurrent anti-platelet therapy and samples with known sensitivity to ibrutinib in terms of platelet functions (92). In clinical trials, most bleeding was low grade presenting as contusion or petechiae. Major bleeding is uncommon with both ibrutinib (2-5%) (93) and acalabrutinib (2-5%) (49, 51). Concurrent administration of warfarin is generally avoided during treatment with BTKis because warfarin was an exclusion criterion for most trials after four patients on a phase 2 study developed subdural hematoma while taking ibrutinib and warfarin or aspirin (94). Direct oral anticoagulants, anti-platelet agents including aspirin and clopidogrel, and low molecular weight heparins can be used during treatment with BTKis (95). Dual anti-platelet therapy is generally avoided given very limited data on safety. Patients undergoing elective surgical procedures are recommended to interrupt BTKis for 3 to 7 days before and after the procedure to minimize the risk of post-operative bleeding.

Hypertension and atrial fibrillation (Afib) are the two most common cardiovascular toxicities of BTKis. In a retrospective analysis of 562 patients treated with ibrutinib, new or worsening hypertension affected 78% of the patients, occurred early in the treatment course (50% of the events occurred within 2 months of...
treatment initiation), and was associated with major cardiovascular events including AfiB (96). Emergence of AfiB during treatment with BTKi poses a particular challenge to clinicians. The complexity of care increases with the diagnosis of AfiB as it requires cardiology consultation, assessment of the need for anticogulation, and rate-and/or rhythm-controlling interventions. Reported incidences of AfiB range from 7-13% in studies of ibrutinib (48, 93, 96) and 3-7% for acalabrutinib (49, 51, 97). This difference in incidences of AfiB can be explained by the fact that ibrutinib, but not acalabrutinib, inhibits C-terminal Src kinase (CSK) expressed in cardiac tissue (28). In support of this hypothesis, CSK knock-out mice, as well as ibrutinib-treated mice with wild-type CSK, developed increased AfiB, recapitulating observations from patients treated with ibrutinib. Results from ongoing randomized studies are eagerly awaited to determine the safety of second-generation BTKis in comparison with ibrutinib (NCT02477696, NCT03734016).

Opportunistic infection (OI) is an uncommon, yet important side effect of BTKis. Although variations in the use of antimicrobial prophylaxis make it difficult to determine the true risk of infection, a study by Rogers et al. reported the OI incidence rate of 1.9 per 100 person-years in a retrospective analysis of over 500 patients treated with BTKis (98). Invasive aspergillosis was the most common pathogen identified from this study (2% of the cohort), while others reported *Pneumocystis jirovecii* pneumonia in up to 3% of patients not on prophylaxis during BTKi therapy (99, 100). Other rare pathogens observed during BTKi therapy include atypical *Mycobacterium* spp., JC virus, and toxoplasmosis (98). Impaired immune surveillance during treatment with a BTKi is linked to the known role of BTK in macrophage toll-like receptor 9 activation (101). BTK deficient mice are unable to mount an immune response to fungus, indicating that BTKis control innate immunity (102).

**DRUG RESISTANCE**

Disease progression remains among the most common reasons for BTKi discontinuation in CLL. Long-term follow-up of patients treated with ibrutinib monotherapy reported 5-year PFS of 70-92% for first-line treatment with ibrutinib (40, 103), and 40-44% for relapsed CLL (43, 103). In addition to prior treatment status, risk of progression increases in the presence of high-risk genetic or biochemical markers at pre-treatment such as *TP53* aberrations (56, 59), complex karyotype (104), increased B-2 microglobulin, and elevated lactate dehydrogenase (105).

There are two types of disease progression on BTKis. First, CLL can histologically transform into a more aggressive type of lymphoma, a phenomenon termed Richter’s transformation (RT). Atypical B cells found in RT commonly have DLBCL-like immunophenotypes and less often present as Hodgkin-like lesions with Reed-Sternberg cells (106). Although mechanisms of histologic transformation are unclear, studies have identified enrichment of several notable molecular events in RT. There is a high prevalence of stereotyped BCR (70%) and biased usage of *IGHV4-39* in patients with RT (107). Mutations of known driver genes in CLL (*TP53, NOTCH1*) and the *CDKN2A/B* cell cycle regulator are found more frequently in RT than CLL (108). RT is further characterized by complex copy number changes including 17p loss leading to *TP53* aberration, gain/amplification of MYC on 8q, 9q loss resulting in haploinsufficiency of *CDKN2A/2B*, and 18p loss without a candidate gene (109). However, these genetic lesions are not unique to RT, raising the possibility of an additional non-genetic inducer of aggressive transformation. Akt-mediated transcriptional control and subsequent NOTCH activation have been recently proposed to have a role in RT, which is supported by increased AKT activation in primary RT samples and an accelerated lymphoma phenotype observed in the Eµ-TCL1 mouse model with constitutive Akt activation (110). Once RT develops during treatment with BTKis, most patients relapse shortly after or become refractory to alternative therapy including immune checkpoint inhibitors (111) and anthracycline-based chemoimmunotherapy (112, 113). Allogeneic stem cell transplant (114) and CD19 chimeric antigen receptor modified T-cell infusion (CAR T) (115) can offer durable remission in a minority of patients. Unfortunately, many patients with RT are deemed unsuitable for cell therapy because of comorbidities, low rates of remission after initial therapy, lack of stem cell donors, or limited access to cellular products.

The second and more commonly observed type of progression is CLL with secondary resistance to BTKis. Up to 80% of the patients with BTKi-resistant CLL carry *BTK* and/or *PLCG2* mutations at the time of progression (Figure 2) (116–118). *BTK* mutations substitute the C481 residue with an alternative amino acid, most commonly serine, leading to the loss of a covalent bond between the drug and the kinase. The vast majority of *PLCG2* mutations identified to date affect the N-terminal SH2 domain with an autoinhibitory function. Functional studies in CLL and autoimmune diseases demonstrated that a mutation or deletion of the SH2 domain...
can activate PLC\(\gamma\)2 and downstream BCR signaling (119–121). Acquisition of \(BTK\) and \(PLCG2\) mutations can occur any time in the clinical course. Preexisting \(BTK\) or \(PLCG2\) mutation is exceedingly rare and comprises a minor fraction of \(CLL\), if any [allele frequency of 0.0002% in a report by Burger et al. (122)]. Under selective pressure of \(BTK\) inhibition, \(CLL\) undergoes linear or branching evolution with the latter giving rise to a multiclonal disease (Figure 3) (118). Multiclonality of \(BTK\)-resistant \(CLL\) was clearly demonstrated by a single-cell analysis of a patient with four different \(PLCG2\) mutations, which presented as distinct clonal subpopulations rather than coexisting mutations within the same cells (122).

Several theoretical approaches can be considered to prevent the emergence of \(BTK\) resistance. The simplest method is to stop \(BTK\)is after a defined period. Another approach is to combine multiple targeted agents with non-overlapping mechanisms of action as discussed previously. Several ongoing trials investigate time-limited, targeted agent-based combination therapy in \(CLL\) (NCT04608318, NCT03701282, NCT02950051). Critical to these approaches is the ability to monitor clonal evolution during and after treatment cessation in both investigational and control arms of these trials.

**OVERCOMING RESISTANCE TO COVALENT BTK INHIBITORS**

\(BTK\)-resistant \(CLL\) demonstrates an aggressive clinical course in the absence of effective salvage therapy (123). Venetoclax can achieve initial responses (124). However, the responses are not durable, and most patients progress within 2 years. Novel combinations are being tested in \(BTK\)-resistant \(CLL\) including

---

**FIGURE 3** | Clonal evolution of \(BTK\)-resistant \(CLL\). Clonal architecture of \(CLL\) changes over time under the selective pressure of treatment and in the presence of driver gene mutations. Panel (A) is a schematic representation of a patient who was treated with chemoimmunotherapy (CIT) as first-line and a \(BTK\) inhibitor (\(BTK\)i) as second-line therapy for \(CLL\). Two lines of therapy selectively expanded a parental clone with a driver gene mutation (\(TP53\) in this case), which became a parental clone of \(BTK\)-resistant disease. Multiple \(BTK\) and \(PLCG2\) mutations arose after branching evolution and were detectable at relatively low allele frequency at the time of progression. Panel (B) shows a patient who underwent a major shift in clonal dominance from one clone (\(SF3B1\) mutation #1) to another (\(SF3B1\) mutation #2) during treatment with a \(BTK\)i. Linear evolution of the emerging clone led to a single dominant \(BTK\) mutation at progression detectable at high allele frequency.
ibrutinib plus venetoclax (NCT03943342, NCT03513562) and umbralisib plus ublituximab (NCT04149821). A phase 2 study of ibrutinib plus duvelisib in ibrutinib-resistant CLL was halted due to sudden death (NCT04209621). It will be of interest to determine the tolerability of novel combinations and the subsequent risk of clonal evolution in patients who became resistant to non-covalent BTKis.

Immune-directed therapy has an advantage over targeted agents as it can bypass resistance mechanisms intrinsic to tumor cells. In the modern era, allogeneic hematopoietic stem cell transplant has become safer and more accessible. Recent retrospective analyses of transplant outcomes in CLL reported 2-year PFS of 63% (125) and 3-year non-relapse mortality of 7% in patients who were previously treated with targeted agents (126). Treatment with CD19 CAR T can also achieve high rates of BTK/PLCG2 mutant CLL cells mediated by cytokine release, and improve access to adoptive cell de

none of the commercially available CD19 CAR T products are approved for the treatment of CLL. Further research is needed to determine the durability of response to CAR T, minimize toxicities mediated by cytokine release, and improve access to adoptive cell therapy. Preclinical data indicate bispecific T-cell engager antibodies targeting CD3 and CD19 are efficacious against BTK/PLCG2 mutant CLL cells in vitro and in patient-derived xenograft models (127). Several bispecific antibodies have entered clinical development to test dual targeting of CD3xCD19 (blinatumomab, NCT02568553), CD3xCD20 (REGN1979, NCT02290951), and CD3xCD22 (INJ-75348780, NCT04540796).

Retargeting of BTK with agents with reversible covalent binding chemistry is an attractive strategy for the treatment of CLL. BTK mutation, found in ~80% of patients with ibrutinib resistance, validates the importance of this kinase in CLL. Reversible BTKis can inhibit the kinase in the presence of BTK C481 mutation (128). Five reversible BTKis have entered clinical trials to date (Table 3). Of these, pirtobrutinib is most advanced in development and most specific to BTK with little to no effect on other targets. In a phase 1/2 study, the overall response rate to pirtobrutinib was 71% for CLL patients with BTK C481 mutation and 66% for those with wild-type BTK, indicating that clinical activity was independent of BTK mutation status (129). MK-1026 (formerly ARQ-531) differs from other reversible BTKis for its ability to inhibit SYK and LYN and indirectly inhibit MEK1/ERK. Intriguingly, MK-1026 inhibited downstream signaling of DT40 cell lines transfected with PLCG2 mutations, suggesting SYK/LYN inhibition has a role against PLCG2 mutant clones (128). A phase 1 study of MK-1026 is expected to complete soon (130) and to be followed by a phase 2 study in hematologic malignancies including CLL (NCT04728893). CG-806 is a dual inhibitor of BTK and FMS-like tyrosine kinase 3 with internal tandem duplication, a mutation found in 30% of patients with acute myeloid leukemia (136). A phase 1 study of CG-806 is ongoing in CLL and non-Hodgkin lymphomas (NCT03893682) (136) besides two additional studies in myeloid diseases. Fenebrutinib (132) and vecabrutinib (135) showed acceptable tolerability in phase 1 studies, but were withdrawn from development in B cell malignancies. Fenebrutinib continues to be tested in multiple trials to date (Table 3). Of these, pirtobrutinib is most advanced in development and most specific to BTK with little to no effect on other targets. In a phase 1/2 study, the overall response rate to pirtobrutinib was 71% for CLL patients with BTK C481 mutation and 66% for those with wild-type BTK, indicating that clinical activity was independent of BTK mutation status (129). MK-1026 (formerly ARQ-531) differs from other reversible BTKis for its ability to inhibit SYK and LYN and indirectly inhibit MEK1/ERK. Intriguingly, MK-1026 inhibited downstream signaling of DT40 cell lines transfected with PLCG2 mutations, suggesting SYK/LYN inhibition has a role against PLCG2 mutant clones (128). A phase 1 study of MK-1026 is expected to complete soon (130) and to be followed by a phase 2 study in hematologic malignancies including CLL (NCT04728893). CG-806 is a dual inhibitor of BTK and FMS-like tyrosine kinase 3 with internal tandem duplication, a mutation found in 30% of patients with acute myeloid leukemia (136). A phase 1 study of CG-806 is ongoing in CLL and non-Hodgkin lymphomas (NCT03893682) (136) besides two additional studies in myeloid diseases. Fenebrutinib (132) and vecabrutinib (135) showed acceptable tolerability in phase 1 studies, but were withdrawn from development in B cell malignancies. Fenebrutinib continues to be tested in multiple trials to date (Table 3). Of these, pirtobrutinib is most advanced in development and most specific to BTK with little to no effect on other targets. In a phase 1/2 study, the overall response rate to pirtobrutinib was 71% for CLL patients with BTK C481 mutation and 66% for those with wild-type BTK, indicating that clinical activity was independent of BTK mutation status (129). MK-1026 (formerly ARQ-531) differs from other reversible BTKis for its ability to inhibit SYK and LYN and indirectly inhibit MEK1/ERK. Intriguingly, MK-1026 inhibited downstream signaling of DT40 cell lines transfected with PLCG2 mutations, suggesting SYK/LYN inhibition has a role against PLCG2 mutant clones (128). A phase 1 study of MK-1026 is expected to complete soon (130) and to be followed by a phase 2 study in hematologic malignancies including CLL (NCT04728893). CG-806 is a dual inhibitor of BTK and FMS-like tyrosine kinase 3 with internal tandem duplication, a mutation found in 30% of patients with acute myeloid leukemia (136). A phase 1 study of CG-806 is ongoing in CLL and non-Hodgkin lymphomas (NCT03893682) (136) besides two additional studies in myeloid diseases. Fenebrutinib (132) and vecabrutinib (135) showed acceptable tolerability in phase 1 studies, but were withdrawn from development in B cell malignancies. Fenebrutinib continues to be tested in multiple...
sclerosis (NCT04586023, NCT04586010). Venclexta was withdrawn due to insufficient evidence of activity limiting its advancement to a phase 2 study (NCT03037645).

CONCLUSION

Data accumulated from clinical trials of covalent BTKIs identified research questions critical for further optimization of the BTK targeting strategy. First, a better distinction of safety and efficacy profiles of individual BTKIs is anticipated through ongoing randomized trials. Second, novel targeted combinations can achieve deep response and enable treatment cessation upon attainment of U-MRD in CLL. What remains to be addressed is durability of response and long-term safety of novel combinations, randomized comparisons with approved BTKi- or BCL-2-based regimens, and clonal dynamics traced with sequential genomic testing. Lastly, treatments capable of preventing or overcoming resistance to covalent BTKIs are urgently needed. Several non-covalent BTKIs with activity against BTKi-resistant disease are currently under investigation, highlighting the importance of BTK as a therapeutic target in CLL.

AUTHOR CONTRIBUTIONS

IA and JB performed literature review and wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

IA is funded by American Society of Hematology Scholar Award. JB is funded by NCI R01 CA 213442.

REFERENCES

1. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic Active B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma. *Nature* (2010) 463(7277):88–92. doi: 10.1038/nature08638
2. Gauld SB, Dal Porto JM, Cambier JC. B Cell Antigen Receptor Signaling: Roles in Cell Development and Disease. *Science* (2002) 296(5573):1614–2. doi: 10.1126/science.1071546
3. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 Kinase Signals BCR-Dependent Mature B Cell Survival. *Cell* (2009) 139 (3):573–86. doi: 10.1016/j.cell.2009.08.041
4. Lam KP, Kuhn R, Rajewsky K. In Vivo Ablation of Surface Immunoglobulin on Mature B-Cells by Inducible Gene Targeting Results in Rapid Cell Death. *Cell* (1997) 90(6):1073–83. doi: 10.1016/S0092-8674(00)80373-6
5. Chen L, Monti S, Juszczynski P, Ouyang I, Chapuy B, Neuberg D, et al. SYK Inhibition Modulates Distinct PI3K/AKT-Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. *Cancer Cell* (2013) 23(6):826–38. doi: 10.1016/j.ccr.2013.05.002
6. Schmitz R, Young RM, Ceribelli M, Jhaveri S, Xiao W, Zhang M, et al. Burkitt Lymphoma Pathogenesis and Therapeutic Targets From Structural and Functional Genomics. *Nature* (2012) 490(7418):116–20. doi: 10.1038/ nature11378
7. Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B, et al. CXCR4 Upregulation is an Indicator of Sensitivity to B-Cell Receptor/PI3K Blockade and a Potential Resistance Mechanism in B-Cell Receptor-Dependent Diffuse Large B-Cell Lymphomas. *Haematologica* (2020) 105 (3):1361–8. doi: 10.3324/haematol.2019.216218
8. Messmer BT, Albessano E, Efermov DG, Ghioth F, Allen SL, Kolitz J, et al. Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia. *J Exp Med* (2004) 200(4):519–25. doi: 10.1084/jem.20040544
9. Navarro A, Clot G, Royo C, Jares P, Hazidehimiriou A, Agathangelidou A, et al. Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. *Cancer Res* (2012) 72(20):5307–16. doi: 10.1158/0008-5472.CAN-12-1615
10. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-Cell Receptor of a Hepatitis C Virus (HCV)-Associated Non-Hodgkin Lymphoma Binds the Viral E2 Envelope Protein, Implicating HCV in Lymphomagenesis. *Blood* (2001) 98(13):3745–9. doi: 10.1182/blood.V98.13.3745
11. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2018) 378(15):1396–407. doi: 10.1056/NEJMoa1801445
12. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated With Distinct Pathogenic Mechanisms and Outcomes. *Nat Med* (2018) 24(5):679–90. doi: 10.1038/s41591-018-0016-8
13. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. *Science* (2008) 319(5870):1676–9. doi: 10.1126/science.1153629
14. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations Driving CLL and Their Evolution in Progression and Relapse. *Nature* (2015) 526(7574):525–30. doi: 10.1038/nature15395
15. Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-Agent Brutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial. *Blood* (2018) 131(2):182–90. doi: 10.1182/blood-2017-09-804641
16. Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of Somatic Mutations and Clonal Evolution in Mantle Cell Lymphoma. *Proc Natl Acad Sci USA* (2013) 110(45):18250–5. doi: 10.1073/pnas.1314608110
17. Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, et al. Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen. *J Immunol* (2013) 190(9):4878–97. doi: 10.4049/ jimmunol.1300179
18. Sachen KL, Strohmjan MJ, Singletary J, Alizadeh AA, Kattah NH, Lossos CI, et al. Self-Antigen Recognition by Follicular Lymphoma B-Cell Receptors. *Blood* (2012) 120(20):4182–90. doi: 10.1182/blood-2012-05-427534
19. Dighiero G, Hart S, Lim A, Borche L, Levy R, Miller RA. Autoantibody Activity of Immunoglobulins Isolated From B-Cell Follicular Lymphomas. *Blood* (1991) 78(3):581–5. doi: 10.1182/blood.V78.3.581.bloodjournal783851
20. Ali K, Sood DR, Pineiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110delta Breaks Regulatory T-Cell-Mediated Immune Tolerance to Cancer. *Nature* (2014) 510(7505):407–11. doi: 10.1038/nature13444
21. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davidso M, et al. Idelalisib Given Front-Line for Treatment of Chronic Lymphocytic Leukemia Causes Frequent Immune-Mediated Hepatotoxicity. *Blood* (2016) 128(2):195–203. doi: 10.1182/blood-2016-03-707133
22. Lampson BL, Brown JR. PI3Kdelta-Selective and PI3Kalpha/delta- Combinatorial Inhibitors in Clinical Development for B-Cell Non-Hodgkin Lymphoma. *Expert Opin Investig Drugs* (2017) 26(11):1267. doi: 10.1080/13543784.2017.1384815
23. Dai B, Grau M, Juillard M, Klenner P, Horing E, Molinsky J, et al. B-Cell Receptor-Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. *Blood* (2017) 129(3):333–46. doi: 10.1182/blood-2016-05-718775
74. Goede V, Fischer K, Bosch F, follows G, Frederiksen H, Cunéo A, et al. Updated Survival Analysis From the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoinmunotherapy-Treated Patients With Chronic Lymphocytic Leukemia. Blood (2015) 126(23):1733. doi: 10.1182/blood.V126.23.1733.1733
75. Marcus R, Davies A, Ando K, Klapper W, Opal S, Owen C, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med (2017) 377(14):1331–44. doi: 10.1056/NEJMoa161498
76. Chu CC, Pinney JJ, Blick-Niski SK, Baran AM, Peterson DR, Whitehead HE, et al. Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis But Not Effectorcytosis of CLL Cells. Blood (2020) 136(SUPPL 1):45. doi: 10.1182/blood-2020-139483
77. Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salen D, et al. Interactions Between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. Clin Cancer Res (2016) 22(1):86–95. doi: 10.1158/1078-0432.CCR-15-1304
78. Pavlasova G, Borsky M, Seda V, Cernk A, Osickova J, Doupek M, et al. Ibrutinib Inhibits CD20 Uptregulation on CLL B Cells Mediated by the CXCR4/SDF-1 Axis. Blood (2016) 128(12):1609–13. doi: 10.1182/blood-2016-04-709519
79. Roberts WA, Ma A, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of Venetoclax in Relapsed Chronic Lymphocytic Leukemia is Influenced by Disease and Response Variables. Blood (2019) 134(2):111–119. doi: 10.1182/blood-2018-09-873271
80. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients With CLL and Coexisting Conditions. N Engl J Med (2019) 380(23):2225–36. doi: 10.1056/NEJMoa1815281
81. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med (2019) 380(22):2095–103. doi: 10.1056/NEJMoa1900574
82. Rogers KA, Huang Y, Rupperst AS, Abruzzo LV, Andersen BL, Awan FT, et al. Antibody-Dependent Cellular Cytotoxicity of the Optimized Anti-CD20 Antibody–Dependent Thrombus Formation In Vivo. Blood (2020) 136(SUPPL 1):20--22. doi: 10.1182/blood-2019-127506
83. Davids MS, Lampson BL, Tyekucheva S, Crombie JJ, Ng S, Kim AI, et al. Updated Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood (2020) 136(SUPPL 1):20–21. doi: 10.1182/blood-2020-139864
84. Soumerai J, Mato A, Carter J, Dogan A, Hochberg E, Barnes J, et al. Initial Results of a Multicenter, Investigator-Initiated Study of MDH Driven TIME Limitation Therapy With Zanubrutinib, Obinutuzumab and Venetoclax. J Clin Oncol (2020) 38(15). doi: 10.1200/JCO.2020.38.15_suppl.L8006.0
85. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, et al. Preliminary Safety and Efficacy Results From a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood (2019) 134(1):32. doi: 10.1182/blood-2019-127506
86. Dimopoulos MA, Tedeschi A, Trotman J, Garcia-Sanz R, Macdonald D, Leblond V, et al. Phase 3 Trial of Ibrutinib Plus Rituximab in Waldenstrom’s Macroglobulinemia. N Engl J Med (2018) 378(25):2399–410. doi: 10.1056/NEJMoa1802917
87. Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinan AM, Nghiem K, et al. Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. Haematologica (2015) 100(12):1571–8. doi: 10.3324/haematol.2015.126672
88. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton Tyrosine Kinase Is Essential for Botrocetin/VWF-Induced Signaling and GPIb-Dependent Thrombus Formation In Vivo. Blood (2006) 108(10):2596–603. doi: 10.1182/blood-2006-01-011817
89. Atkinson BT, Ellmeier W, Watson SP. Tec Regulates Platelet Activation by GPVI in the Absence of Btk. Blood (2006) 108(8):2596–603. doi: 10.1182/blood-2006-01-011817
90. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib Inhibits Collagen-Mediated But Not ADP-Mediated Platelet Aggregation. Leukemia (2015) 29(4):783–7. doi: 10.1038/leu.2014.247
124. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for Chronic Lymphocytic Leukaemia Progressing After Ibrutinib: An Interim Analysis of a Multicentre, Open-Label, Phase 2 Trial. *Lancet Oncol* (2018) 19(1):65–75. doi: 10.1016/S1470-2045(17)30909-9
125. Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, et al. Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukaemia in the Era of Novel Agents. *Blood Adv* (2020) 4(16):3977–89. doi: 10.1182/bloodadvances.2020001956
126. Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, et al. Allogeneic Hematopoietic Cell Transplantation After Prior Targeted Therapy for High-Risk Chronic Lymphocytic Leukemia. *Blood Adv* (2020) 4(17):4113–23. doi: 10.1182/bloodadvances.2020002184
127. Robinson HR, Qi J, Cook EM, Nichols C, Dadashian EL, Underbayev C, et al. A CD19/CD3 Bispecific Antibody for Effective Immunotherapy of Chronic Lymphocytic Leukemia in the Ibrutinib Era. *Blood* (2018) 132(5):521–32. doi: 10.1182/blood-2018-02-830992
128. Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. *Cancer Discovery* (2018) 8(10):1300–15. doi: 10.1158/2159-8290.CD-17-1409
129. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies (BRUIN): A Phase 1/2 Study. *Lancet* (2021) 397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5
130. Woyach J, Stephens DM, Flynn JW, Bhat SA, Savage RE, Chai F, et al. Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients With Relapsed or Refractory B-cell Lymphoid Malignancies. *Blood* (2019) 134. doi: 10.1182/blood-2019-127260
131. Bejar R, Zhang H, Rastgoor N, Benbatoul K, Jin Y, Thayer M, et al. Phase 1a/ B Dose Escalation Study of the Mutation agnostic BTK/FLT3 Inhibitor CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin’s Lymphomas. *Blood* (2020) 136(SUPPL 1):35. doi: 10.1182/blood-2020-141495
132. Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-Human Phase 1 Study of the BTK Inhibitor GDC-0853 in Relapsed or Refractory B-Cell NHL and CLL. *Oncotarget* (2018) 9(16):13023–35. doi: 10.18632/oncotarget.24310
133. Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, et al. Noncovalent Inhibition of C481S Bruton Tyrosine Kinase by GDC-0853: A New Treatment Strategy for Ibrutinib-Resistant CLL. *Blood* (2018) 132(10):1039–49. doi: 10.1182/blood-2017-10-809020
134. Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development. *J Med Chem* (2018) 61(6):2227–45. doi: 10.1021/acs.jmedchem.7b01712
135. Allan JN, Patel K, Mato AR, Wierda WG, Ibarz JP, Choi MY, et al. Ongoing Results of a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies. *Blood* (2019) 134. doi: 10.1097/ 01.HS9.0000562876.57990.65
136. Zhang H, Rastgoor N, Benbatoul K, Sheng S, Thayer M, Bejar R, et al. Early Clinical Findings From a Phase 1a/B Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With Relapsed or Refractory CLL/SLL or non-Hodgkin’s Lymphomas. *Cancer Res* (2020) 80(16 SUPPL). doi: 10.1158/1538-7445.AM2020-CT239

Conflict of Interest: JB has served as a consultant for Abbvie, Acerta, AstraZeneca, Beigene, Catapult, Dynamo Therapeutics, Eli Lilly, Genentech/Roche, Juno/Celgene/Bristol Myers Squibb, Kite, Loxo, MEI Pharma, Nextacea, Novartis, Pfizer, Pharmacyclics, Rigel, Sunesis, TG Therapeutics; received research funding from Gilead, Loxo, SPARC, TG Therapeutics and Verastem; and served on data safety monitoring committees for Invectys.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Ahn and Brown. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.